Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease.
Level III
Where this comes from
- Record sourced from PubMed, PMID 31351682.
- Also identified by DOI 10.1016/j.jpeds.2019.06.018.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Compared with a 5% intravenous immunoglobulin, a 10% intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035). There were no severe adverse events.
Medical subject headings
- Immunoglobulins, Intravenous
- Mucocutaneous Lymph Node Syndrome